KemPharm/ZVRA

$4.80

-2.83%
-
1D1W1MYTD1YMAX

About KemPharm

Zevra Therapeutics, Inc. is a rare disease company melding science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA. Its pipeline also includes EDSIVO and others.

Ticker

ZVRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Neil Mcfarlane

Employees

65

Headquarters

Celebration, United States
Website
zevra.com

KemPharm Metrics

BasicAdvanced
$208.45M
Market cap
-
P/E ratio
-$1.29
EPS
1.86
Beta
-
Dividend rate
$208.45M
1.8602
$7.28
$3.89
244.93K
1.179
68.295
-32.02%
-67.23%
-45.61%
7.591
3.223
170.26%
-65.64%
27.38%

What the Analysts think about KemPharm

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
295.83% upside
High $24.00
Low $15.00
$4.80
Current price
$19.00
Average price target

KemPharm Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-114.39% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$13.2M
371.43%
Net income
$-15.1M
7.86%
Profit margin
-114.39%
-77.12%

KemPharm Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 49.07%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.34
-$0.15
-$0.40
-$0.40
-
Expected
-$0.23
-$0.34
-$0.30
-$0.27
-$0.48
Surprise
46.24%
-56.31%
34.45%
49.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for KemPharm stock?

KemPharm (ZVRA) has a market cap of $208.45M as of April 14, 2024.

What is the P/E ratio for KemPharm stock?

The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of April 14, 2024.

Does KemPharm stock pay dividends?

No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next KemPharm dividend payment date?

KemPharm (ZVRA) stock does not pay dividends to its shareholders.

What is the beta indicator for KemPharm?

KemPharm (ZVRA) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the KemPharm stock price target?

The target price for KemPharm (ZVRA) stock is $19, which is 295.83% above the current price of $4.8. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell KemPharm stock

Buy or sell KemPharm stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing